To evaluate the clinical benefit of extended endocrine therapy after 5 years of adjuvant treatment with LHRHa in premenopausal women with node-positive, HR-positive early breast cancer.

Investigators sought to describe the patterns of post-progression outcome for patients with HR+/HER2- advanced breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its ...

Conclusions The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer. (ClinicalTrials.gov ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

Among breast cancer survivors who became pregnant, 34% resumed endocrine therapy (ET) by 2 years postdelivery, with a 19% cumulative incidence of subsequent breast cancer events at 10 years. The ...